The mechanisms of methotrexate’s action in the treatment of inflammatory disease

[1]  M. Weinblatt,et al.  Inhibition of leukotriene B4 synthesis in neutrophils from patients with rheumatoid arthritis by a single oral dose of methotrexate. , 2010, Arthritis and rheumatism.

[2]  G. Alarcón,et al.  Suppression of rheumatoid factor production by methotrexate in patients with rheumatoid arthritis. Evidence for differential influences of therapy and clinical status on IgM and IgA rheumatoid factor expression. , 2010, Arthritis and rheumatism.

[3]  B. Cronstein,et al.  Reversal of the antiinflammatory effects of methotrexate by the nonselective adenosine receptor antagonists theophylline and caffeine: evidence that the antiinflammatory effects of methotrexate are mediated via multiple adenosine receptors in rat adjuvant arthritis. , 2000, Arthritis and rheumatism.

[4]  Kollias,et al.  Methotrexate specifically modulates cytokine production by T cells and macrophages in murine collagen‐induced arthritis (CIA): a mechanism for methotrexate‐mediated immunosuppression , 1999, Clinical and experimental immunology.

[5]  J. Dobson,et al.  Adenosine A2a receptors increase arterial endothelial cell nitric oxide. , 1998, The Journal of surgical research.

[6]  S. Morgan,et al.  The effect of methotrexate and 7-hydroxymethotrexate on rat adjuvant arthritis and on urinary aminoimidazole carboxamide excretion. , 1998, Arthritis and rheumatism.

[7]  L. Genestier,et al.  Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. , 1998, The Journal of clinical investigation.

[8]  R. Quinn,et al.  Adenosine receptors: new opportunities for future drugs. , 1998, Bioorganic & medicinal chemistry.

[9]  M. Heenen,et al.  Methotrexate induces apoptotic cell death in human keratinocytes , 1998, Archives of Dermatological Research.

[10]  B. Dijkmans,et al.  Methotrexate reduces inflammatory cell numbers, expression of monokines and of adhesion molecules in synovial tissue of patients with rheumatoid arthritis. , 1998, British journal of rheumatology.

[11]  B. Cronstein,et al.  Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5'-nucleotidase-mediated conversion of adenine nucleotides. , 1998, The Journal of clinical investigation.

[12]  J. Bondeson.  The mechanisms of action of disease-modifying antirheumatic drugs: a review with emphasis on macrophage signal transduction and the induction of proinflammatory cytokines. , 1997, General pharmacology.

[13]  B. Cronstein,et al.  Adenosine A1 receptor promotion of multinucleated giant cell formation by human monocytes. A mechanism for methotrexate‐induced nodulosis in rheumatoid arthritis , 1997 .

[14]  D. Boyle,et al.  Adenosine inhibits neutrophil degranulation in activated human whole blood: involvement of adenosine A2 and A3 receptors. , 1997, Journal of immunology.

[15]  M. Jacobson,et al.  Adenosine A2a receptor activation delays apoptosis in human neutrophils. , 1997, Journal of immunology.

[16]  S. Moochhala,et al.  Adenosine and its receptor agonists potentiate nitric oxide synthase expression induced by lipopolysaccharide in RAW 264.7 murine macrophages. , 1997, Life sciences.

[17]  V. Riccieri,et al.  Relationship of soluble interleukin-2-receptor and interleukin-6 with class-specific rheumatoid factors during low-dose methotrexate treatment in rheumatoid arthritis. , 1997, Revue du rhumatisme.

[18]  M. Hori,et al.  Adenosine inhibits leukocyte-induced vasoconstriction. , 1996, The American journal of physiology.

[19]  I. Laurindo,et al.  Low dose methotrexate decreases intraarticular prostaglandin and interleukin 1 levels in antigen induced arthritis in rabbits. , 1996, The Journal of rheumatology.

[20]  J. Mierau,et al.  In vivo role of the adenosine A3 receptor: N6-2-(4-aminophenyl)ethyladenosine induces bronchospasm in BDE rats by a neurally mediated mechanism involving cells resembling mast cells. , 1996, The Journal of pharmacology and experimental therapeutics.

[21]  E. Vizi,et al.  Adenosine receptor agonists differentially regulate IL-10, TNF-alpha, and nitric oxide production in RAW 264.7 macrophages and in endotoxemic mice. , 1996, Journal of immunology.

[22]  H. Sato,et al.  Adenosine A2-receptor activation inhibits neutrophil-mediated injury to coronary endothelium. , 1996, The American journal of physiology.

[23]  F. Belloc,et al.  Effect of buflomedil on the neutrophil-endothelial cell interaction under inflammatory and hypoxia conditions. , 1996, Haemostasis.

[24]  G. Firestein,et al.  Inhibition of synoviocyte collagenase gene expression by adenosine receptor stimulation. , 1996, Arthritis and rheumatism.

[25]  M. Thiel,et al.  Effect of adenosine on the expression of β2 integrins and L‐selectin of human polymorphonuclear leukocytes in vitro , 1996, Journal of leukocyte biology.

[26]  R. K. Shepherd,et al.  Adenosine-induced vasoconstriction in vivo. Role of the mast cell and A3 adenosine receptor. , 1996, Circulation research.

[27]  J. Fozard,et al.  Mast cell degranulation following adenosine A3 receptor activation in rats. , 1996, European journal of pharmacology.

[28]  W. Buurman,et al.  Adenosine inhibits cytokine release and expression of adhesion molecules by activated human endothelial cells. , 1996, The American journal of physiology.

[29]  M. Beaven,et al.  Sustained activation of phospholipase D via adenosine A3 receptors is associated with enhancement of antigen- and Ca(2+)-ionophore-induced secretion in a rat mast cell line. , 1996, The Journal of pharmacology and experimental therapeutics.

[30]  J. Merrill,et al.  Selection of a gene for apolipoprotein A1 using autoantibodies from a patient with systemic lupus erythematosus. , 1995, Arthritis and rheumatism.

[31]  T. Schnitzer,et al.  Double-blind, placebo-controlled multicenter trial using chimeric monoclonal anti-CD4 antibody, cM-T412, in rheumatoid arthritis patients receiving concomitant methotrexate. , 1995, Arthritis and rheumatism.

[32]  I. Biaggioni,et al.  Adenosine A2b receptors evoke interleukin-8 secretion in human mast cells. An enprofylline-sensitive mechanism with implications for asthma. , 1995, The Journal of clinical investigation.

[33]  B. Dijkmans,et al.  A randomized, double-blind, placebo-controlled study of CD4 monoclonal antibody therapy in early rheumatoid arthritis. , 1995, Arthritis and rheumatism.

[34]  P. van Riel,et al.  Effect of methotrexate alone or in combination with sulphasalazine on the production and circulating concentrations of cytokines and their antagonists. Longitudinal evaluation in patients with rheumatoid arthritis. , 1995, British journal of rheumatology.

[35]  B. Dewald,et al.  Methotrexate action in rheumatoid arthritis: stimulation of cytokine inhibitor and inhibition of chemokine production by peripheral blood mononuclear cells. , 1995, British Journal of Rheumatology.

[36]  J. Fozard,et al.  A role for mast cells in adenosine A3 receptor‐mediated hypotension in the rat , 1995, British journal of pharmacology.

[37]  S. Baumgartner-Parzer,et al.  Stimulation of human umbilical vein endothelial cell proliferation by A2‐adenosine and β2‐adrenoceptors , 1995, British journal of pharmacology.

[38]  M. Feldmann,et al.  Monoclonal anti‐TNFα Antibody as a Probe of Pathogenesis and Therapy of Rheumatoid Disease , 1995, Immunological reviews.

[39]  B. Williams,et al.  The effect of liposomally conjugated methotrexate upon mediator release from human peripheral blood monocytes. , 1995, British journal of rheumatology.

[40]  R. Madhok,et al.  Interleukin 6 (IL-6) and soluble IL-2 receptor levels in patients with rheumatoid arthritis treated with low dose oral methotrexate. , 1995, The Journal of rheumatology.

[41]  M. Erion,et al.  Inhibition of neutrophil adhesion by adenosine and an adenosine kinase inhibitor. The role of selectins. , 1995, Journal of immunology.

[42]  N. Topley,et al.  Prostaglandin and tumor necrosis factor secretion by peritoneal macrophages isolated from normal and arthritic rats treated with liposomal methotrexate. , 1994, Journal of pharmacological and toxicological methods.

[43]  O. Stendahl,et al.  The role of cyclic AMP, calcium and filamentous actin in adenosine modulation of Fc receptor-mediated phagocytosis in human neutrophils. , 1994, Biochimica et biophysica acta.

[44]  R. Sauerwein,et al.  Interference of circulating azathioprine but not methotrexate or sulfasalazine with measurements of interleukin-6 bioactivity. , 1994, Lymphokine and cytokine research.

[45]  B. Dewald,et al.  Monocyte chemoattractant protein 1 and interleukin 8 production by rheumatoid synoviocytes. Effects of anti-rheumatic drugs. , 1994, Cytokine.

[46]  G. Firestein,et al.  Mechanisms of methotrexate action in rheumatoid arthritis. Selective decrease in synovial collagenase gene expression. , 1994, Arthritis and rheumatism.

[47]  N. Topley,et al.  Effect of liposomally encapsulated MTX-DMPE conjugates upon TNF alpha and PGE2 release by lipopolysaccharide stimulated rat peritoneal macrophages. , 1994, Biochimica et biophysica acta.

[48]  B. Cronstein,et al.  The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. , 1993, The Journal of clinical investigation.

[49]  R. Kimberly,et al.  Human mononuclear phagocytes express adenosine A1 receptors. A novel mechanism for differential regulation of Fc gamma receptor function. , 1993, Journal of immunology.

[50]  J. Meer,et al.  Circulating soluble tumor necrosis factor receptors, interleukin‐2 receptors, tumor necrosis factor α, and interleukin‐6 levels in rheumatoid arthritis. , 1993 .

[51]  J. Smith,et al.  Acting via A2 receptors, adenosine inhibits the upregulation of Mac-1 (Cd11b/CD18) expression on FMLP-stimulated neutrophils. , 1993, American journal of respiratory cell and molecular biology.

[52]  M. F. Ethier,et al.  Adenosine stimulates proliferation of human endothelial cells in culture. , 1993, The American journal of physiology.

[53]  T. Smith-Oliver,et al.  Elevated levels of TNF in the joints of adjuvant arthritic rats. , 1993, Cytokine.

[54]  P. Schur,et al.  The effects of methotrexate on interleukin 1 in patients with rheumatoid arthritis. , 1992, The Journal of rheumatology.

[55]  A. Malaviya,et al.  Methotrexate: clinical and immunological effects in refractory rheumatoid arthritis. , 1992, The Journal of the Association of Physicians of India.

[56]  C. Chavis,et al.  Effects of a single dose of methotrexate on 5- and 12-lipoxygenase products in patients with rheumatoid arthritis. , 1992, The Journal of rheumatology.

[57]  T. Ochi,et al.  Polyamine levels in synovial tissues and synovial fluids of patients with rheumatoid arthritis. , 1992, The Journal of rheumatology.

[58]  M. Weinblatt,et al.  Acute and chronic suppression of leukotriene B4 synthesis ex vivo in neutrophils from patients with rheumatoid arthritis beginning treatment with methotrexate. , 1992, Arthritis and rheumatism.

[59]  S. Abramson,et al.  Neutrophil adherence to endothelium is enhanced via adenosine A1 receptors and inhibited via adenosine A2 receptors. , 1992, Journal of immunology.

[60]  E. Flescher,et al.  Regulation of IL‐2 production by mononuclear cells from rheumatoid arthritis synovial fluids , 1992, Clinical and experimental immunology.

[61]  J. Richter.  Effect of adenosine analogues and cAMP‐raising agents on TNF‐, GM‐CSF–, and chemotactic peptide–induced degranulation in single adherent neutrophils , 1992, Journal of leukocyte biology.

[62]  K. Klotz,et al.  Carbamazepine distinguishes between adenosine receptors that mediate different second messenger responses. , 1991, European journal of pharmacology.

[63]  B. Cronstein,et al.  Fc gamma receptor-mediated functions in neutrophils are modulated by adenosine receptor occupancy. A1 receptors are stimulatory and A2 receptors are inhibitory. , 1990, Journal of immunology.

[64]  P. Schur,et al.  The effect of antirheumatic drugs on interleukin 1 (IL-1) activity and IL-1 and IL-1 inhibitor production by human monocytes. , 1990, The Journal of rheumatology.

[65]  T. Moore,et al.  The in vitro effects of methotrexate on peripheral blood mononuclear cells. Modulation by methyl donors and spermidine. , 1990, Arthritis and rheumatism.

[66]  R. DiGiacomo,et al.  Dietary fish oil and olive oil supplementation in patients with rheumatoid arthritis. Clinical and immunologic effects. , 1990, Arthritis and rheumatism.

[67]  B. Cronstein,et al.  The adenosine/neutrophil paradox resolved: human neutrophils possess both A1 and A2 receptors that promote chemotaxis and inhibit O2 generation, respectively. , 1990, The Journal of clinical investigation.

[68]  B. E. Huber,et al.  3-deazaadenosine inhibits leukocyte adhesion and ICAM-1 biosynthesis in tumor necrosis factor-stimulated human endothelial cells. , 1990, Journal of immunology.

[69]  G. Schmid-Schoenbein,et al.  Increased adenosine concentration in blood from ischemic myocardium by AICA riboside. Effects on flow, granulocytes, and injury. , 1989, Circulation.

[70]  M. Yaron,et al.  Synovial and serum levels of methotrexate during methotrexate therapy of rheumatoid arthritis. , 1989, British journal of rheumatology.

[71]  N. Olsen,et al.  Antiproliferative effects of methotrexate on peripheral blood mononuclear cells. , 1989, Arthritis and rheumatism.

[72]  E. Flescher,et al.  Increased polyamines may downregulate interleukin 2 production in rheumatoid arthritis. , 1989, The Journal of clinical investigation.

[73]  M. Yaron,et al.  The effects of methotrexate on the production and activity of interleukin-1. , 1989, Arthritis and rheumatism.

[74]  A. Stephenson,et al.  Regulation of human neutrophil functions by adenine nucleotides. , 1989, Journal of immunology.

[75]  P. Keller,et al.  3-Deazaadenosine 5'-triphosphate: a novel metabolite of 3-deazaadenosine in mouse leukocytes. , 1989, Biochemical pharmacology.

[76]  S. B. Kramer,et al.  Occupancy of adenosine receptors raises cyclic AMP alone and in synergy with occupancy of chemoattractant receptors and inhibits membrane depolarization. , 1988, The Biochemical journal.

[77]  G. Weissmann,et al.  Adenosine promotes neutrophil chemotaxis , 1988, The Journal of experimental medicine.

[78]  M. Weinblatt,et al.  Long-term prospective trial of low-dose methotrexate in rheumatoid arthritis. , 1988, Arthritis and rheumatism.

[79]  T. Pincus,et al.  Immunologic studies of rheumatoid arthritis patients treated with methotrexate. , 1987, Arthritis and rheumatism.

[80]  J. Kremer,et al.  Fish-oil fatty acid supplementation in active rheumatoid arthritis. A double-blinded, controlled, crossover study. , 1987, Annals of internal medicine.

[81]  L. Thomas,et al.  Methylxanthine bronchodilators potentiate multiple human neutrophil functions. , 1987, Journal of immunology.

[82]  G. Weissmann,et al.  Adenosine: an endogenous inhibitor of neutrophil-mediated injury to endothelial cells. , 1986, The Journal of clinical investigation.

[83]  H. Stevenson,et al.  Synergistic action of adenosine and fMet-Leu-Phe in raising cAMP content of purified human monocytes. , 1986, Biochemical and biophysical research communications.

[84]  J. Baggott,et al.  Inhibition of 5-aminoimidazole-4-carboxamide ribotide transformylase, adenosine deaminase and 5'-adenylate deaminase by polyglutamates of methotrexate and oxidized folates and by 5-aminoimidazole-4-carboxamide riboside and ribotide. , 1986, The Biochemical journal.

[85]  J. Kurtzberg,et al.  Abnormalities in S‐Adenosylhomocysteine Hydrolysis, ATP Catabolism, and Lymphoid Differentiation in Adenosine Deaminase Deficiency a , 1985, Annals of the New York Academy of Sciences.

[86]  G. Curt,et al.  Polyglutamation of methotrexate. Is methotrexate a prodrug? , 1985, The Journal of clinical investigation.

[87]  C. Allegra,et al.  Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[88]  T. Zimmerman,et al.  3-Deazaadenosine-induced disorganization of macrophage microfilaments. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[89]  K. Whaley,et al.  Adenosine A2 receptors on human monocytes modulate C2 production. , 1984, Clinical and experimental immunology.

[90]  S. B. Kramer,et al.  Adenosine: a physiological modulator of superoxide anion generation by human neutrophils , 1983, The Journal of experimental medicine.

[91]  L. Lichtenstein,et al.  The role of agonists that activate adenylate cyclase in the control of cAMP metabolism and enzyme release by human polymorphonuclear leukocytes. , 1980, Journal of immunology.

[92]  M. Hershfield,et al.  S-adenosylhomocysteine toxicity in normal and adenosine kinase-deficient lymphoblasts of human origin. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[93]  M. Hershfield,et al.  In vivo inactivation of erythrocyte S-adenosylhomocysteine hydrolase by 2'-deoxyadenosine in adenosine deaminase-deficient patients. , 1979, The Journal of clinical investigation.

[94]  G. S. Duncan,et al.  Inhibition of lymphocyte-mediated cytolysis by 3-deazaadenosine: evidence for a methylation reaction essential to cytolysis. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[95]  M. Hershfield,et al.  S-adenosylhomocysteine hydrolase is an adenosine-binding protein: a target for adenosine toxicity. , 1978, Science.

[96]  A. Luhby,et al.  Aminoimidazolecarboxamide excretion in vitamin-B12 and folic-acid deficiencies. , 1962, Lancet.

[97]  B. Mazières,et al.  Antiinflammatory and immunoregulatory action of methotrexate in the treatment of rheumatoid arthritis: evidence of increased interleukin-4 and interleukin-10 gene expression demonstrated in vitro by competitive reverse transcriptase-polymerase chain reaction. , 1998, Arthritis and rheumatism.

[98]  H. Sato,et al.  Adenosine A2 receptor activation attenuates reperfusion injury by inhibiting neutrophil accumulation, superoxide generation and coronary endothelial adherence. , 1997, The Journal of pharmacology and experimental therapeutics.

[99]  N. Olsen,et al.  Associations of IgA and IgA-rheumatoid factor with disease features in patients with rheumatoid arthritis. , 1994, Immunological investigations.

[100]  L. Cleland,et al.  The effect of methotrexate on ex vivo lipoxygenase metabolism in neutrophils from patients with rheumatoid arthritis. , 1994, The Journal of rheumatology.

[101]  I. Böhm,et al.  Mechanism of Action of Methotrexate: Experimental Evidence that Methotrexate Blocks the Binding of Interleukin 1β to the Interleukin 1 Receptor on Target Cells , 1993, European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies.

[102]  R. Turner,et al.  Biochemical perturbations of BW 91Y (3-deazaadenosine) on human neutrophil chemotactic potential and lipid metabolism. , 1991, International journal of tissue reactions.

[103]  E. Flescher,et al.  Abnormalities of T cell activation in the rheumatoid synovium detected with monoclonal antibodies to CD3. , 1988, Scandinavian journal of rheumatology. Supplement.

[104]  W. J. Johnson,et al.  Methotrexate inhibits macrophage activation as well as vascular and cellular inflammatory events in rat adjuvant induced arthritis. , 1988, The Journal of rheumatology.

[105]  F. Bloom.  Neurotransmitters and CNS disease. The future. , 1982, Lancet.